Clear Search

Showing 1 result for “Psachoulia K”.

Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

J Comp Eff Res. 2022;11(10):765–777 doi: 10.2217/cer-2022-0040

Population-adjusted comparative study provides insights for decision makers and clinicians about the comparative efficacy of anifrolumab and belimumab in patients with moderate-to-severe systemic lupus erythematosus (SLE) who are receiving standard therapy.

In the absence of head-to-head comparisons, Bruce, et al. assessed the comparative efficacy of the two biological therapies currently approved in the EU and USA for the treatment of moderate-to-severe SLE (anifrolumab 300 mg and belimumab 10 mg/kg).

After adjusting for important cross-trial differences, their results showed that anifrolumab was associated with significantly greater treatment benefits than belimumab.

Read more…